Robert Radinsky

14.2k total citations · 2 hit papers
127 papers, 10.4k citations indexed

About

Robert Radinsky is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Robert Radinsky has authored 127 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 57 papers in Molecular Biology and 39 papers in Cancer Research. Recurrent topics in Robert Radinsky's work include Cancer, Hypoxia, and Metabolism (32 papers), HER2/EGFR in Cancer Research (18 papers) and Colorectal Cancer Treatments and Studies (17 papers). Robert Radinsky is often cited by papers focused on Cancer, Hypoxia, and Metabolism (32 papers), HER2/EGFR in Cancer Research (18 papers) and Colorectal Cancer Treatments and Studies (17 papers). Robert Radinsky collaborates with scholars based in United States, Australia and Italy. Robert Radinsky's co-authors include Daniel J. Freeman, Todd Juan, Rafael G. Amado, Marc Peeters, Eric Van Cutsem, Michael Wolf, David Chang, Robert Sikorski, Sid Suggs and Scott D. Patterson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Robert Radinsky

126 papers receiving 10.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

2008 2.4k citations Rafael G. Amado, Michael Wolf et al. Journal of Clinical Oncology profile →
Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression

1995 615 citations Laurie B. Owen‐Schaub, Wei Zhang et al. Molecular and Cellular Biology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Robert Radinsky	6.3k	4.5k	2.5k	2.2k	1.5k	127	10.4k
Gabriella Fontanini	7.2k 1.2×	5.3k 1.2×	4.7k 1.9×	2.7k 1.2×	1.6k 1.1×	320	13.4k
Wells A. Messersmith	5.3k 0.9×	4.3k 1.0×	1.8k 0.7×	1.7k 0.7×	1.2k 0.8×	298	9.5k
Livio Trusolino	4.4k 0.7×	4.9k 1.1×	1.7k 0.7×	2.2k 1.0×	1.3k 0.9×	135	10.2k
Hartmut Koeppen	5.0k 0.8×	4.9k 1.1×	1.5k 0.6×	1.7k 0.8×	910 0.6×	116	9.2k
Johanna C. Bendell	9.4k 1.5×	5.4k 1.2×	4.3k 1.8×	2.1k 0.9×	2.0k 1.4×	535	14.8k
Federica Di Nicolantonio	7.6k 1.2×	4.7k 1.0×	3.5k 1.4×	3.6k 1.6×	3.3k 2.2×	114	11.8k
Frédéric Bibeau	6.3k 1.0×	3.3k 0.7×	2.4k 1.0×	3.0k 1.3×	2.5k 1.7×	193	10.7k
Massimo Roncalli	4.7k 0.8×	3.2k 0.7×	3.3k 1.3×	1.8k 0.8×	1.2k 0.8×	228	11.5k
Robert L. Camp	5.7k 0.9×	6.2k 1.4×	2.3k 0.9×	2.4k 1.1×	1.0k 0.7×	118	12.8k
Michael S. O’Reilly	3.4k 0.5×	7.5k 1.7×	2.1k 0.9×	4.6k 2.1×	583 0.4×	79	12.0k

Countries citing papers authored by Robert Radinsky

Since Specialization

Citations

This map shows the geographic impact of Robert Radinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Radinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Radinsky more than expected).

Fields of papers citing papers by Robert Radinsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Radinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Radinsky. The network helps show where Robert Radinsky may publish in the future.

Co-authorship network of co-authors of Robert Radinsky

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Radinsky. A scholar is included among the top collaborators of Robert Radinsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Radinsky. Robert Radinsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hughes, Paul E., Karen Rex, Sean Caenepeel, et al.. (2016). In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models. Molecular Cancer Therapeutics. 15(7). 1568–1579. 44 indexed citations

Canon, Jude, Tao Osgood, Steven H. Olson, et al.. (2015). The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. Molecular Cancer Therapeutics. 14(3). 649–658. 116 indexed citations

Payton, Marc, Dongyin Yu, Raffi Manoukian, et al.. (2014). Antagonism of Ang-Tie2 and Dll4-Notch signaling has opposing effects on tumor endothelial cell proliferation, evidenced by a new flow cytometry method. Laboratory Investigation. 94(11). 1296–1308. 5 indexed citations

Moody, Gordon, Pedro J. Beltran, Petia Mitchell, et al.. (2014). IGF1R blockade with ganitumab results in systemic effects on the GH–IGF axis in mice. Journal of Endocrinology. 221(1). 145–155. 19 indexed citations

Juan, Gloria, Tammy L. Bush, Raffi Manoukian, et al.. (2014). AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues. Journal of Translational Medicine. 12(1). 307–307. 10 indexed citations

Bush, Tammy L., Marc Payton, Scott Heller, et al.. (2013). AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models. Molecular Cancer Therapeutics. 12(11). 2356–2366. 44 indexed citations

Boedigheimer, Michael, et al.. (2013). Gene Expression Profiles Can Predict Panitumumab Monotherapy Responsiveness in Human Tumor Xenograft Models. Neoplasia. 15(2). 125–132. 5 indexed citations

Coxon, Angela, James Bready, Stephen A. Kaufman, et al.. (2012). Anti-tumor activity of motesanib in a medullary thyroid cancer model.. PubMed. 35(2). 181–90. 22 indexed citations

Freeman, Daniel J., Kevin S. McDorman, Carl J. Kozlosky, et al.. (2012). Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Molecular Cancer. 11(1). 47–47. 24 indexed citations

10.

Carnahan, Josette, Pedro J. Beltran, Carol Babij, et al.. (2010). Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth. Molecular Cancer Therapeutics. 9(8). 2399–2410. 58 indexed citations

11.

Beltran, Pedro J., Petia Mitchell, Elaina Cajulis, et al.. (2009). AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Molecular Cancer Therapeutics. 8(5). 1095–1105. 113 indexed citations

12.

Amado, Rafael G., Michael Wolf, Marc Peeters, et al.. (2008). Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology. 26(10). 1626–1634. 2400 indexed citations breakdown →

13.

Freeman, Daniel J., et al.. (2008). Fully human Anti-HER3 monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor activities versus other HER family inhibitors. Cancer Research. 68. 19 indexed citations

14.

Juan, Todd, et al.. (2007). Association of somatic kRAS gene mutations and clinical outcome from a phase 2 mCRC trial of panitumumab. Clinical Cancer Research. 13. 1 indexed citations

15.

Beltran, Pedro J., Petia Mitchell, David Hwang, et al.. (2007). Inhibition of endocrine IGF-1 signaling in normal murine tissues and human tumor xenografts with AMG 479, a fully human anti IGF-1R monoclonal antibody. Molecular Cancer Therapeutics. 6. 4 indexed citations

16.

Moody, Gordon, Petia Mitchell, Elaina Cajulis, et al.. (2007). AMG 479, a fully human anti IGF-1 receptor monoclonal antibody, is efficacious against Ewing’s sarcoma and osteosarcoma xenografts. Molecular Cancer Therapeutics. 6. 6 indexed citations

17.

Kaufman, Stephen A., Charlie Starnes, Angela Coxon, et al.. (2006). AMG 706 induces the rapid destruction of tumor microvessels in nude mice. Cancer Research. 66. 892–892. 2 indexed citations

18.

Singh, Rakesh K., Rachel Tsan, & Robert Radinsky. (1997). Influence of the host microenvironment on the clonal selection of human colon carcinoma cells during primary tumor growth and metastasis. Clinical & Experimental Metastasis. 15(2). 140–150. 40 indexed citations

19.

Bucana, C, Robert Radinsky, Zhongyun Dong, et al.. (1996). Maintenance of Intestinal Epithelium Structural Integrity and Mucosal Leukocytes During Chemotherapy by Oral Administration of Muramyl Tripeptide Phosphatidylethanolamine. Cancer Biotherapy and Radiopharmaceuticals. 11(6). 363–371. 4 indexed citations

20.

Owen‐Schaub, Laurie B., Wei Zhang, James C. Cusack, et al.. (1995). Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression. Molecular and Cellular Biology. 15(6). 3032–3040. 615 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact